European regulators described their skepticism about the data behind Amgen’s Tavneos (avacopan) in newly released documents, explaining the rationale for pulling the drug from the market in Europe. The coverage focuses on the regulator’s detailed concerns rather than a single adverse event summary, indicating that evidentiary support fell short in key areas. The documents reinforce how regulators are increasingly scrutinizing trial design, dataset integrity, and consistency when assessing benefit-risk—especially in rare and specialist indications. The outcome leaves Amgen facing additional strategic pressure as companies adjust regulatory submissions, conduct supplemental analyses, or pivot to alternative evidence packages.